BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 10089921)

  • 1. Detection of cytomegalovirus proteins by flow cytometry in the blood of patients undergoing hematopoietic stem cell transplantation.
    Detrick B; Hooks JJ; Keiser J; Tabbara I
    Exp Hematol; 1999 Mar; 27(3):569-75. PubMed ID: 10089921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction.
    Yakushiji K; Gondo H; Kamezaki K; Shigematsu K; Hayashi S; Kuroiwa M; Taniguchi S; Ohno Y; Takase K; Numata A; Aoki K; Kato K; Nagafuji K; Shimoda K; Okamura T; Kinukawa N; Kasuga N; Sata M; Harada M
    Bone Marrow Transplant; 2002 Apr; 29(7):599-606. PubMed ID: 11979310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR.
    Schulenburg A; Watkins-Riedel T; Greinix HT; Rabitsch W; Loidolt H; Keil F; Mitterbauer M; Kalhs P
    Bone Marrow Transplant; 2001 Oct; 28(8):765-8. PubMed ID: 11781628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study.
    Junghanss C; Boeckh M; Carter RA; Sandmaier BM; Maris MB; Maloney DG; Chauncey T; McSweeney PA; Little MT; Corey L; Storb R
    Blood; 2002 Mar; 99(6):1978-85. PubMed ID: 11877269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
    Tan BH; Chlebicka NL; Low JG; Chong TY; Chan KP; Goh YT
    Transpl Infect Dis; 2008 Oct; 10(5):325-32. PubMed ID: 18627578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation.
    Solano C; Muñoz I; Gutiérrez A; Farga A; Prósper F; García-Conde J; Navarro D; Gimeno C
    J Clin Microbiol; 2001 Nov; 39(11):3938-41. PubMed ID: 11682510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant.
    Marchesi F; Pimpinelli F; Ensoli F; Mengarelli A
    Hematol Oncol; 2018 Apr; 36(2):381-391. PubMed ID: 28660653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation.
    Asano-Mori Y; Oshima K; Sakata-Yanagimoto M; Nakagawa M; Kandabashi K; Izutsu K; Hangaishi A; Motokura T; Chiba S; Kurokawa M; Hirai H; Kanda Y
    Bone Marrow Transplant; 2005 Nov; 36(9):813-9. PubMed ID: 16151428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring of CMV infection: a comparison of PCR from whole blood, plasma-PCR, pp65-antigenemia and virus culture in patients after bone marrow transplantation.
    Hebart H; Müller C; Löffler J; Jahn G; Einsele H
    Bone Marrow Transplant; 1996 May; 17(5):861-8. PubMed ID: 8733710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation.
    Bacigalupo A; Bregante S; Tedone E; Isaza A; Van Lint MT; Trespi G; Occhini D; Gualandi F; Lamparelli T; Marmont AM
    Transplantation; 1996 Aug; 62(3):376-80. PubMed ID: 8779686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus DNAemia detected with real-time polymerase chain reaction in hematopoietic stem cell transplant patients.
    Sahin DG; Gunduz E; Kasifoglu N; Akay OM; Us T; Gulbas Z
    Adv Ther; 2013 Aug; 30(8):784-91. PubMed ID: 23959787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of PCR serum in diagnosing and monitoring cytomegalovirus reactivation in bone marrow transplant recipients.
    Matsunaga T; Sakamaki S; Ishigaki S; Kohda K; Takeda M; Katoh J; Kuroda H; Hirayama Y; Kusakabe T; Akiyama T; Kuga T; Niitsu Y; Masaoka T; Sagawa T; Matsumoto Y
    Int J Hematol; 1999 Feb; 69(2):105-11. PubMed ID: 10071460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic Utility of Cytomegalovirus Nucleic Acid Testing during Antigenemia-Guided Cytomegalovirus Monitoring after Hematopoietic Stem Cell Transplantation or Liver Transplantation.
    Morinaga Y; Sawayama Y; Hidaka M; Mori S; Taguchi J; Takatsuki M; Eguchi S; Miyazaki Y; Yanagihara K
    Tohoku J Exp Med; 2019 Mar; 247(3):179-187. PubMed ID: 30890664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction?
    Kekre N; Tokessy M; Mallick R; McDiarmid S; Huebsch L; Bredeson C; Allan D; Tay J; Tinmouth A; Sheppard D
    Biol Blood Marrow Transplant; 2013 Dec; 19(12):1719-24. PubMed ID: 24099958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay.
    Lo CY; Ho KN; Yuen KY; Lui SL; Li FK; Chan TM; Lo WK; Cheng IK
    Clin Transplant; 1997 Aug; 11(4):286-93. PubMed ID: 9267717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing of CMV-specific effector memory T cells predicts viral replication and survival after allogeneic hematopoietic stem cell transplantation.
    Espigado I; de la Cruz-Vicente F; BenMarzouk-Hidalgo OJ; Gracia-Ahufinger I; Garcia-Lozano JR; Aguilar-Guisado M; Cisneros JM; Urbano-Ispizua A; Perez-Romero P
    Transpl Int; 2014 Dec; 27(12):1253-62. PubMed ID: 25070273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.
    Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T
    Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CMV antigenemia and quantitative viral load assessments in hematopoietic stem cell transplant recipients.
    Cardeñoso L; Pinsky BA; Lautenschlager I; Aslam S; Cobb B; Vilchez RA; Hirsch HH
    J Clin Virol; 2013 Feb; 56(2):108-12. PubMed ID: 23146665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: a single-center experience.
    Manteiga R; Martino R; Sureda A; Labeaga R; Brunet S; Sierra J; Rabella N
    Bone Marrow Transplant; 1998 Nov; 22(9):899-904. PubMed ID: 9827819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practices for cytomegalovirus diagnosis, prophylaxis and treatment in allogeneic bone marrow transplant recipients: a report from the Working Party for Infectious Diseases of the EBMT.
    Ljungman P; De Bock R; Cordonnier C; Einsele H; Engelhard D; Grundy J; Locasciulli A; Reusser P; Ribaud P
    Bone Marrow Transplant; 1993 Oct; 12(4):399-403. PubMed ID: 8275040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.